Citation: Tc. Dowling et al., SIMULTANEOUS DETERMINATION OF P-AMINOHIPPURIC ACID, ACETYL-P-AMINOHIPPURIC ACID AND IOTHALAMATE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, Journal of chromatography B. Biomedical sciences and applications, 716(1-2), 1998, pp. 305-313
Citation: Rf. Frye et al., A SENSITIVE METHOD FOR THE SIMULTANEOUS DETERMINATION OF CAFFEINE ANDITS DIMETHYLXANTHINE METABOLITES IN HUMAN PLASMA - APPLICATION TO CYP1A2 PHENOTYPING, Journal of liquid chromatography & related technologies, 21(8), 1998, pp. 1161-1171
Citation: Je. Murphy et al., EVALUATION OF GENTAMICIN PHARMACOKINETICS AND DOSING PROTOCOLS IN 195NEONATES, American journal of health-system pharmacy, 55(21), 1998, pp. 2280-2288
Citation: A. Adedoyin et al., CHLOROQUINE MODULATION OF SPECIFIC METABOLIZING ENZYMES ACTIVITIES - INVESTIGATION WITH SELECTIVE 5 DRUG COCKTAIL, British journal of clinical pharmacology, 46(3), 1998, pp. 215-219
Citation: Ma. Marx et al., CEFAZOLIN AS EMPIRIC THERAPY IN HEMODIALYSIS-RELATED INFECTIONS - EFFICACY AND BLOOD-CONCENTRATIONS, American journal of kidney diseases, 32(3), 1998, pp. 410-414
Citation: Ms. Joy et al., DETERMINANTS OF VANCOMYCIN CLEARANCE BY CONTINUOUS VENOVENOUS HEMOFILTRATION AND CONTINUOUS VENOVENOUS HEMODIALYSIS, American journal of kidney diseases, 31(6), 1998, pp. 1019-1027
Authors:
FRYE RF
ADEDOYIN A
MAURO K
MATZKE GR
BRANCH RA
Citation: Rf. Frye et al., USE OF CHLORZOXAZONE AS AN IN-VIVO PROBE OF CYTOCHROME-P450 2E1 - CHOICE OF DOSE AND PHENOTYPIC TRAIT MEASURE, Journal of clinical pharmacology, 38(1), 1998, pp. 82-89
Authors:
BURCKART GJ
FRYE RF
KELLY P
BRANCH RA
JAIN A
FUNG JJ
STARZL TE
VENKATARAMANAN R
Citation: Gj. Burckart et al., INDUCTION OF CYP2E1 ACTIVITY IN LIVER-TRANSPLANT PATIENTS AS MEASUREDBY CHLORZOXAZONE 6-HYDROXYLATION, Clinical pharmacology and therapeutics, 63(3), 1998, pp. 296-302
Authors:
FRYE RF
BERTZ RJ
GRANNEMAN GR
LAUVA I
LAMM J
DENNIS S
VALDES J
Citation: Rf. Frye et al., EFFECT OF RITONAVIR ON CYP1A2, 2C19, AND 2E1 ACTIVITIES IN-VIVO, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 44-44
Authors:
ADEDOYIN A
TRUMP DL
BRUFSKY A
FRYE RF
HOFACKER J
BRANCH RA
Citation: A. Adedoyin et al., SELECTIVE ALTERATION OF SPECIFIC METABOLIZING ENZYME-ACTIVITIES BY DISULFIRAM AND KETOCONAZOLE, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 67-67
Citation: Ma. Marx et al., CEFAZOLIN FOR EMPIRIC TREATMENT OF HD-RELATED INFECTIONS - EFFICACY AND BLOOD-CONCENTRATIONS, Journal of the American Society of Nephrology, 8, 1997, pp. 939-939
Citation: Gr. Matzke et Rf. Frye, DRUG ADMINISTRATION IN PATIENTS WITH RENAL-INSUFFICIENCY - MINIMIZINGRENAL AND EXTRARENAL TOXICITY, Drug safety, 16(3), 1997, pp. 205-231
Authors:
FRYE RF
MATZKE GR
ADEDOYIN A
PORTER JA
BRANCH RA
Citation: Rf. Frye et al., VALIDATION OF THE 5-DRUG PITTSBURGH COCKTAIL APPROACH FOR ASSESSMENT OF SELECTIVE REGULATION OF DRUG-METABOLIZING-ENZYMES, Clinical pharmacology and therapeutics, 62(4), 1997, pp. 365-376
Citation: Tc. Dowling et al., PAH RENAL CLEARANCE AFTER AN IV BOLUS IS NOT AN ACCURATE MARKER OF ERPF, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 83-83
Authors:
FRYE RF
MATZKE GR
SCHADE R
DIXON R
RABINOVITZ M
Citation: Rf. Frye et al., EFFECTS OF LIVER-DISEASE ON THE DISPOSITION OF THE OPIOID ANTAGONIST NALMEFENE, Clinical pharmacology and therapeutics, 61(1), 1997, pp. 15-23
Citation: Rf. Frye et Dd. Stiff, DETERMINATION OF CHLORZOXAZONE AND 6-HYDROXYCHLORZOXAZONE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, Journal of chromatography B. Biomedical applications, 686(2), 1996, pp. 291-296
Citation: Rf. Frye et Ra. Branch, IMPROVED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF DEBRISOQUINE AND 4-HYDROXYDEBRISOQUINE IN HUMAN URINE FOLLOWING DIRECT-INJECTION, Journal of chromatography B. Biomedical applications, 677(1), 1996, pp. 178-182
Citation: Gr. Matzke et al., DETERMINANTS OF CEFTRIAXONE CLEARANCE BY CVVHD AND CVVH, Journal of the American Society of Nephrology, 7(9), 1996, pp. 1359-1359
Citation: Gr. Matzke et al., CLEARANCE OF CEFTAZIDIME (TAZ) BY CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH) AND HEMODIALYSIS (CVVHD), Journal of the American Society of Nephrology, 7(9), 1996, pp. 1360-1360
Citation: Tc. Dowling et al., RENAL CLEARANCES OF AMINOHIPPURATE AND ITS ACETYLATED METABOLITE IN PATIENTS WITH LIVER-DISEASE, Journal of the American Society of Nephrology, 7(9), 1996, pp. 1653-1653
Authors:
FRYE RF
MATZKE GR
JALLAD NS
WILHELM JA
BIKHAZI GB
Citation: Rf. Frye et al., THE EFFECT OF AGE ON THE PHARMACOKINETICS OF THE OPIOID ANTAGONIST NALMEFENE, British journal of clinical pharmacology, 42(3), 1996, pp. 301-306
Authors:
MATZKE GR
FRYE RF
ALEXANDER ACM
REYNOLDS R
DIXON R
JOHNSTON J
RAULT RM
Citation: Gr. Matzke et al., THE EFFECT OF RENAL-INSUFFICIENCY AND HEMODIALYSIS ON THE PHARMACOKINETICS OF NALMEFENE, Journal of clinical pharmacology, 36(2), 1996, pp. 144-151
Authors:
KARARA AH
FRYE RF
HAYES PE
WEAVER ML
ROBINSON WT
RAULT RM
MATZKE GR
Citation: Ah. Karara et al., PHARMACOKINETICS OF ABECARNIL IN PATIENTS WITH RENAL-INSUFFICIENCY, Clinical pharmacology and therapeutics, 59(5), 1996, pp. 520-528